Discover
SNOA
Sonoma Pharmaceuticals, Inc.
1.21
2 x 0.88
3 x 1.84
bid
ask
-
0.02
1.63%
3 @ 05:55 AM
1.18 -0.03 (2.46%)
| Ytd | -66.76% | |
| 1y | -58.98% |
1.20
day range
1.23
0.85
52 week range
6.92
| Open | 1.21 | Prev Close | 1.23 | Low | 1.20 | High | 1.23 | Mkt Cap | 5.79M |
| Vol | 59.56K | Avg Vol | 237.62K | EPS | -1.89 | P/E | N/A | Forward P/E | -1.49 |
| Beta | 1.38 | Short Ratio | 0.22 | Inst. Own | 2.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.19 | 200-d Avg | 2.77 | 1yr Est | 19.50 |
SNOA News
benzinga.com
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance For Its Microdacyn Wound Irrigation Solution
Clearance includes expanded claims, clearance for multiple use, and additional packaging configurati
accessnewswire.com
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for
BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global
benzinga.com
Sonoma Pharmaceuticals Q4 EPS $(0.33) Misses $(0.24) Estimate, Sales $5.561M Miss $5.565M Estimate
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.33) per share which missed the